Drug Regulation

FDA Quality Control Clinical Trials Prescription Painkillers FDA Approval DEA FDA Oversight Psychedelic Therapy Controlled Substances Pharmaceutical Oversight FDA Operations FDA Approval Process Synthetic Opioids

Biogen Licenses Vanqua’s Preclinical C5aR1 Drug in Deal Worth Up to $1.06 Billion

The company is targeting an FDA IND in 2027 contingent on supportive preclinical data.